DOXYLAMINE SUCCINATE

US Approved OTC

First approved in 1948

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H22N2O.C4H6O4
Molecular Weight	388.4574
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2

InChI

InChIKey=KBAUFVUYFNWQFM-UHFFFAOYSA-N

InChI=1S/C17H22N2O.C4H6O4/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16;5-3(6)1-2-4(7)8/h4-12H,13-14H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H22N2O
Molecular Weight	270.3694
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB00366
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/doxylamine.html

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic. Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects. Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: https://pubmed.ncbi.nlm.nih.gov/23357028/	Antagonist 2778		42.0 nM [Ki]
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: https://pubmed.ncbi.nlm.nih.gov/23357028/	Antagonist 2778		200.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Allergic rhinitis 100 Sources: https://www.drugs.com/cdi/doxylamine.html	Primary		Approved 8429	Unisom Approved Use Allergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies Insomnia (tablets only): Reduce difficulty falling asleep Launch Date 2.56089604E11
Insomnia 108 Sources: https://www.drugs.com/cdi/doxylamine.html	Primary		Approved 8429	Unisom Approved Use Allergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies Insomnia (tablets only): Reduce difficulty falling asleep Launch Date 2.56089604E11

C_max

Value	Dose	Co-administered	Analyte	Population
18.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	6.3 mg single, nasal dose: 6.3 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
27.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	12.7 mg single, nasal dose: 12.7 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
142 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	3.2 mg single, nasal dose: 3.2 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
124.91 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
61.94 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
99 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4056080/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
83.3 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIDOXINE HYDROCHLORIDE	PYRIDOXINE HYDROCHLORIDE	DOXYLAMINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
168.6 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: PYRIDOXINE HYDROCHLORIDE	PYRIDOXINE HYDROCHLORIDE	DOXYLAMINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
117.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	6.3 mg single, nasal dose: 6.3 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
161.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	12.7 mg single, nasal dose: 12.7 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
751.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
81.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	3.2 mg single, nasal dose: 3.2 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1697.58 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
859.74 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1280.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIDOXINE HYDROCHLORIDE	PYRIDOXINE HYDROCHLORIDE	DOXYLAMINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
3721.5 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: PYRIDOXINE HYDROCHLORIDE	PYRIDOXINE HYDROCHLORIDE	DOXYLAMINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	6.3 mg single, nasal dose: 6.3 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	12.7 mg single, nasal dose: 12.7 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/	3.2 mg single, nasal dose: 3.2 mg route of administration: Nasal experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4056080/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DOXYLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIDOXINE HYDROCHLORIDE	PYRIDOXINE HYDROCHLORIDE	DOXYLAMINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
11.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: PYRIDOXINE HYDROCHLORIDE	PYRIDOXINE HYDROCHLORIDE	DOXYLAMINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25661472 Page: p.179	unknown, 2 n = 1 Health Status: unknown Age Group: 2 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25661472 Page: p.179	Other AEs: Agitation, Dilated pupils... Other AEs: Agitation Dilated pupils Sources: https://pubmed.ncbi.nlm.nih.gov/25661472 Page: p.179
25 mg single, oral Studied dose Dose: 25 mg Route: oral Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23633146 Page: p.133	healthy, 28 - 58 n = 12 Health Status: healthy Age Group: 28 - 58 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/23633146 Page: p.133	Other AEs: Somnolence... Other AEs: Somnolence (50%) Sources: https://pubmed.ncbi.nlm.nih.gov/23633146 Page: p.133
12.7 mg single, intranasal Highest studied dose Dose: 12.7 mg Route: intranasal Route: single Dose: 12.7 mg Sources: https://pubmed.ncbi.nlm.nih.gov/29671128 Page: p.133	unhealthy, 35.9 (8.00) n = 24 Health Status: unhealthy Condition: Chronic intermittent sleep impairment Age Group: 35.9 (8.00) Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/29671128 Page: p.133	Sources: https://pubmed.ncbi.nlm.nih.gov/29671128 Page: p.133
13 mg/kg single, oral Overdose Dose: 13 mg/kg Route: oral Route: single Dose: 13 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29196111 Page: p.1	unknown Health Status: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/29196111 Page: p.1	Other AEs: Rhabdomyolysis... Other AEs: Rhabdomyolysis Sources: https://pubmed.ncbi.nlm.nih.gov/29196111 Page: p.1
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.1	Other AEs: Somnolence... Other AEs: Somnolence Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.1
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) CNS depressants Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.3	Other AEs: Drowsiness... Other AEs: Drowsiness (grade 3) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.3
20 mg single, oral Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.48	healthy n = 48 Health Status: healthy Sex: F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.48	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.48
20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63	healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63	Disc. AE: Vomiting, Decreased hemoglobin... AEs leading to discontinuation/dose reduction: Vomiting Decreased hemoglobin Visual impairment Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63

AEs

AE	Significance	Dose	Population
Agitation		150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25661472 Page: p.179	unknown, 2 n = 1 Health Status: unknown Age Group: 2 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25661472 Page: p.179
Dilated pupils		150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25661472 Page: p.179	unknown, 2 n = 1 Health Status: unknown Age Group: 2 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25661472 Page: p.179
Somnolence	50%	25 mg single, oral Studied dose Dose: 25 mg Route: oral Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23633146 Page: p.133	healthy, 28 - 58 n = 12 Health Status: healthy Age Group: 28 - 58 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/23633146 Page: p.133
Rhabdomyolysis		13 mg/kg single, oral Overdose Dose: 13 mg/kg Route: oral Route: single Dose: 13 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29196111 Page: p.1	unknown Health Status: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/29196111 Page: p.1
Somnolence		20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.1
Drowsiness	grade 3	20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) CNS depressants Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf Page: p.3
Vomiting	Disc. AE	20 mg single, oral Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.48	healthy n = 48 Health Status: healthy Sex: F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.48
Decreased hemoglobin	Disc. AE	20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63	healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63
Visual impairment	Disc. AE	20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63	healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63
Vomiting	Disc. AE	20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63	healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf Page: p.63

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
		CYP2B 32 CYP3A 129 CYP1A 56 CYP2E 9 CYP4A 14

Drug as perpetrator

Target	Modality	Activity
CYP1A 121	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/	no
CYP2E 13	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/	no
CYP4A 33	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/	no
CYP2B 40	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/	yes
CYP3A 298	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:51380	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51380
ChemicalBook	CB6316736	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6316736
MolPort	MolPort-005-935-542	https://www.molport.com/shop/molecule-link/MolPort-005-935-542
eMolecules	901808	https://www.emolecules.com/cgi-bin/more?vid=901808

PubMed

Title	Date	PubMed
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.	2001 Apr	11340978
A fast and efficient determination of amines and preservatives in cough and cold liquid and suspension formulations using a single isocratic ion-pairing high performance [correction of power] liquid chromatography method.	2001 Aug	11451651
Alternative therapies of morning sickness.	2001 Dec	11600848
Return of the morning sickness pill. Could Bendectin be coming back to market?	2001 Feb-Mar	11941692
The expert witness. Neither Frye nor Daubert solved the problem: what can be done?	2001 Jan-Mar	11215302
Quantitation of antihistamines in pharmaceutical preparations by liquid chromatography with a micellar mobile phase of sodium dodecyl sulfate and pentanol.	2001 Nov-Dec	11767132
Pharmacologic interventions in the treatment of temporomandibular disorders, atypical facial pain, and burning mouth syndrome. A qualitative systematic review.	2003 Fall	14737874
Bendectin and birth defects. II: Ecological analyses.	2003 Feb	12769504
Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically.	2004 Jul-Aug	15236716
[Efficacy of donormil in the treatment of insomnia in patients with vascular encephalopathy].	2006	16608114
Analysis of pharmaceutical preparations containing antihistamine drugs by micellar liquid chromatography.	2006 Feb 13	16182504
Therapy insight: drugs for gastrointestinal disorders in pregnant women.	2006 May	16673005
Characterization of antihistamine-human serum protein interactions by capillary electrophoresis.	2007 Apr 20	17339039
Inactivation of anthracyclines by serum heme proteins.	2007 Jun	17497896
Simultaneous determination of a ternary mixture of doxylamine succinate, pyridoxine hydrochloride, and folic acid by the ratio spectra-zero-crossing, double divisor-ratio spectra derivative, and column high-performance liquid chromatographic methods.	2008 Sep-Oct	18980119
Comparison of chiral separation of basic drugs in capillary electrophoresis and liquid chromatography using neutral and negatively charged cyclodextrins.	2009 Jul 10	19481637
The identification of ingested dandelion juice in gastric contents of a deceased person by direct sequencing and GC-MS methods.	2009 May	19432748
Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin.	2010 Apr	20406541
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.	2010 Dec	20843504
A tendency for re-offending in drug-facilitated crime.	2010 Mar 20	20116946
Clinical practice. Nausea and vomiting in pregnancy.	2010 Oct 14	20942670

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Allergic Rhinitis Doxylamine 5 mg oral tablet, chewable: 10 mg orally every 4 to 6 hours not to exceed 6 doses daily. Usual Adult Dose for Allergic Conjunctivitis Doxylamine 5 mg oral tablet, chewable: 10 mg orally every 4 to 6 hours not to exceed 6 doses daily. Usual Adult Dose for Insomnia 12 years of age and older: 25 mg orally 30 minutes before bed

Route of Administration: Oral

In Vitro Use Guide

Doxylamine at 50 ug/ml inhibited both differentiation and proliferation in rat embryo limb bud cell cultures

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:01:13 UTC 2023` Edited by `admin` on `Fri Dec 15 15:01:13 UTC 2023`
Record UNII	V9BI9B5YI2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DOXYLAMINE SUCCINATE

Common Name

English

DORMIDINA

Brand Name

English

MERAPRINA

Brand Name

English

UNISOM

Brand Name

English

DOXYLAMINE SUCCINATE [USP MONOGRAPH]

Common Name

English

DICLECTIN COMPONENT DOXYLAMINE SUCCINATE

Brand Name

English

DONORMYL

Brand Name

English

DOXYLAMINE SUCCINATE COMPONENT OF DICLEGIS

Brand Name

English

ALSODORM

Brand Name

English

DOXYLAMINE SUCCINATE COMPONENT OF BONJESTA

Brand Name

English

DOXYLAMINE SUCCINATE [USP-RS]

Common Name

English

DICLEGIS COMPONENT DOXYLAMINE SUCCINATE

Brand Name

English

DOXYLAMINE SUCCINATE [ORANGE BOOK]

Common Name

English

GITTALUN

Brand Name

English

DOXYLAMINE SUCCINATE [GREEN BOOK]

Common Name

English

DECAPRYN

Brand Name

English

DOXYLAMINE HYDROGEN SUCCINATE [EP MONOGRAPH]

Common Name

English

DOXYLAMINE SUCCINATE COMPONENT OF BENDECTIN

Common Name

English

DOXY-SLEEP-AID

Brand Name

English

N,N-DIMETHYL-2-((1RS)-1-PHENYL-1-(PYRIDIN-2-YL)ETHOXY(ETHANAMINE HYDROGEN BUTANEDIOATE

Common Name

English

DOXYLAMINE SUCCINATE [MART.]

Common Name

English

Doxylamine succinate [WHO-DD]

Common Name

English

DOXYLAMINE HYDROGEN SUCCINATE

Common Name

English

NSC-74772

Code

English

DOXYLAMINE SUCCINATE [VANDF]

Common Name

English

DOXYLAMINE SUCCINATE [IARC]

Common Name

English

HOGGAR N

Brand Name

English

BONJESTA COMPONENT DOXYLAMINE SUCCINATE

Brand Name

English

DECAMIUM

Systematic Name

English

DOXYLAMINE SUCCINATE [MI]

Common Name

English

DOXYLAMINE HYDROGEN SUCCINATE [EP IMPURITY]

Common Name

English

DONORMIL

Brand Name

English

2-[α[2-(Dimethylamino)ethoxy]-α-methylbenzyl]pyridine succinate (1:1)

Systematic Name

English

BENDECTIN COMPONENT DOXYLAMINE SUCCINATE

Brand Name

English

ETHANAMINE, N,N-DIMETHYL-2-(1-PHENYL-1-(2-PYRIDINYL)ETHOXY)-, BUTANEDIOATE (1:1)

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578